SCAF1 Inhibitors

Chemical inhibitors of SCAF1 can exert their inhibitory effects through a variety of mechanisms, each related to the protein's reliance on proper mitochondrial function and ATP availability. Oligomycin A, a known ATP synthase inhibitor, can disrupt the ATP production process, depriving SCAF1 of the energy necessary for its ATP-dependent conformational changes, which are essential for its function within the mitochondrial matrix. Similarly, Antimycin A targets complex III of the mitochondrial electron transport chain, leading to a blockade of electron flow and an ensuing drop in ATP synthesis, which can compromise the stability and function of SCAF1. Carboxin takes aim at succinate dehydrogenase, part of complex II, and its inhibition results in reduced electron transport chain activity and subsequent ATP generation, which is crucial for SCAF1's activity.

Rotenone, by selectively targeting complex I, and Piericidin A, through a similar mechanism, lead to diminished ATP levels that are fundamental for SCAF1's roles within the cell. Thenoyltrifluoroacetone (TTFA) also disrupts complex II, attenuating ATP production and thus indirectly inhibiting SCAF1 by limiting its energy supply. Aurovertin B further inhibits ATP synthase, impacting ATP-dependent interactions vital for SCAF1. Atovaquone acts on cytochrome b in complex III, affecting ATP synthesis, which in turn can restrict the function of SCAF1. Stigmatellin, targeting the ubiquinol oxidation site, and Myxothiazol, inhibiting at the cytochrome b-c1 site of complex III, both reduce ATP synthesis, which is necessary for SCAF1's activity. Azoxystrobin disrupts mitochondrial respiration, also at complex III, leading to a reduction in ATP production that SCAF1 requires. Finally, Iodoacetamide modifies cysteine residues, which can alter critical cysteine-dependent sites on SCAF1 and inhibit its proper functioning within its biological context.